Emyria has engaged PsychoGenics, a leader in Artificial Intelligence (AI) enabled drug discovery and preclinical contract research services in neuroscience to help advance its MDMA-inspired New Drug Discovery program.

PsychoGenics will use its proprietary SmartCube(™) platform to study novel compounds from Emyria’s MDMA-inspired drug discovery program developed with partner the University of Western Australia.

Study results are expected to help Emyria select promising drug candidates for clinical studies and help both parties evaluate the potential for a partnership to accelerate development and commercialisation of the broader MDMA-inspired library.

Read more: https://investorhub.emyria.com/4203061